Belite Bio Inc

NASDAQ:BLTEUnited States

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, LBS-008 as an oral daily treatment for STGD1 and Geographic Atrophy patients. In STGD1, it is developing LBS-008 as once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4 which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009 an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

Contact Information

Headquarters

12750 High Bluff Drive Suite 475SAN DIEGO, CA, United States 92130

Phone

858-246-6240

Fax

---

Executives

Chairman of the Board, Chief Executive Officer

Yu-Hsin Lin

Chief Financial Officer, Director

Hao-Yuan Chuang

Chief Scientific Officer

Nathan Mata

Vice President of Clinical Operations

Ching- Chen Chiu

Vice President of Pharmaceutical Sciences

Wei-cheng Liaw